Fig. 3
From: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Potential intrinsic immune response landscapes in NOTCH4-WT and NOTCH4-MUT tumors. A Comparison of the TMB between NOTCH4-WT and NOTCH4-MUT tumors in the discovery cohort. B Comparison of the TMB between NOTCH4-WT and NOTCH4-MUT tumors in the validation cohort. C Comparison of the nonsilent mutation rate between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. D Comparison of the silent mutation rate between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. E Comparison of SNV neoantigens between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. F Comparison of indel neoantigens between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. G Comparison of the expression of MHC molecules and costimulators between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. H Comparison of the expression of PD-1 between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. I Comparison of the expression of PD-L1 between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. J Comparison of the expression of CTLA-4 between NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. Statistical analysis of comparisons between two groups was conducted using the Wilcoxon test